CASI Pharmaceuticals Net Income From Continuing Ops Over Time
| CASI Stock | USD 0.99 0.03 2.94% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out CASI Pharmaceuticals Performance and CASI Pharmaceuticals Correlation. Is there potential for Biotechnology market expansion? Will CASI introduce new products? Factors like these will boost the valuation of CASI Pharmaceuticals. Projected growth potential of CASI fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about CASI Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.02) | Revenue Per Share | Quarterly Revenue Growth (0.60) | Return On Assets | Return On Equity |
Investors evaluate CASI Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating CASI Pharmaceuticals' intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause CASI Pharmaceuticals' market price to deviate significantly from intrinsic value.
It's important to distinguish between CASI Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding CASI Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, CASI Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Net Income From Continuing Ops Analysis
Compare CASI Pharmaceuticals and related stocks such as Clearside Biomedical, Cingulate, and Entero Therapeutics Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CING | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | (7.2 M) | (20.7 M) | (17.7 M) | (21.2 M) | (15.5 M) | (14 M) | (14.7 M) |
| CRIS | (9.9 M) | (9.9 M) | (16.4 M) | (12.3 M) | (18.7 M) | (59 M) | (60.4 M) | (53.3 M) | (32.6 M) | (32.1 M) | (29.9 M) | (45.4 M) | (56.7 M) | (47 M) | (43.4 M) | (39.1 M) | (41 M) |
| PTHS | (595.4 K) | (595.4 K) | (595.4 K) | (595.4 K) | (595.4 K) | (595.4 K) | (595.4 K) | (595.4 K) | (595.4 K) | (595.4 K) | (595.4 K) | (595.4 K) | (2.5 M) | (7.4 M) | (8 M) | (7.2 M) | (7.5 M) |
| NCNA | (9.6 M) | (9.6 M) | (9.6 M) | (9.6 M) | (9.6 M) | (25.2 M) | (6 M) | (23.1 M) | (13.8 M) | (21.4 M) | (30.7 M) | (40.5 M) | (32 M) | (27.6 M) | (19 M) | (17.1 M) | (18 M) |
| PALI | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (26.6 M) | (14.3 M) | (12.3 M) | (14.4 M) | (16.6 M) | (17.4 M) |
| ALLR | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (5.1 M) | (26.6 M) | (16.1 M) | (13 M) | (24.5 M) | (22.1 M) | (23.2 M) |
| KAPA | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (2.1 M) | (1.1 M) | (1.8 M) | (2.6 M) | (2.3 M) | (2.5 M) |
| LSTA | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (19.4 M) | (8.1 M) | (27.5 M) | (54.2 M) | (20.8 M) | (20 M) | (18 M) | (18.9 M) |
CASI Pharmaceuticals and related stocks such as Clearside Biomedical, Cingulate, and Entero Therapeutics Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| CASI Pharmaceuticals | CASI |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 1701-1702, China Central |
| Exchange | NASDAQ Exchange |
USD 0.99
Check out CASI Pharmaceuticals Performance and CASI Pharmaceuticals Correlation. For more detail on how to invest in CASI Stock please use our How to Invest in CASI Pharmaceuticals guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
CASI Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.